# EDGAR Filing Document

**Accession Number:** 0001860657
**File Stem:** 0001213900-25-061639
**Filing Date:** 2025-7
**Character Count:** 69626
**Document Hash:** 332c969bfcf6f77ed001d98f8b1ffcd7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-061639.hdr.sgml**: 20250707

**ACCESSION NUMBER**: 0001213900-25-061639

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250630

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250707

**DATE AS OF CHANGE**: 20250707

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Allarity Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001860657
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41160
- **FILM NUMBER:** 251107063

**BUSINESS ADDRESS:**
- **STREET 1:** 24 SCHOOL ST., 2ND FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108
- **BUSINESS PHONE:** 401-426-4664

**MAIL ADDRESS:**
- **STREET 1:** 24 SCHOOL ST., 2ND FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **June 30, 2025**

**ALLARITY THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41160** | **87-2147982** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

**123 E Tarpon Ave,** 

**Tarpon Springs, FL 34689**

(Address of principal executive offices)

**<u>(401) 426-4664</u>**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | ALLR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Departure of Chief Financial Officer*

On June 30, 2025, Alexander Epshinsky, Chief Financial Officer of Allarity Therapeutics, Inc. (the "Company"), resigned from the Company. The resignation was not the result of any disagreement with the Company regarding its operations, policies or practices, including accounting principles, practices or disclosures.

 

*Appointment of Chief Financial Officer*

On July 1, 2025, Jeffrey S. Ervin (age 48) was appointed to the office of Chief Financial Officer ("CFO") of the Company, to serve as the Company's CFO on a part-time basis.

Prior to joining the Company, Mr. Ervin served as founder and chief executive officer of Sanaregen Vision Therapeutics, Inc., a clinical-stage biopharmaceutical research and development company, in February 2025 to current day in a fractional capacity. From June 2024 to January 2025, Mr. Ervin served in a fractional capacity as co-chief financial officer of DDC Enterprise, Ltd (NYSE: DDC), a consumer food company. From February 2015 and May 2024, Mr. Ervin served as chairman and chief executive officer of IMAC Holdings, Inc., a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments. Mr. Ervin was co-founder of IMAC Holdings, Inc. and led an initial public offering in February 2019 (Nasdaq: BACK). Mr. Ervin earned his M.B.A. from Vanderbilt University. Mr. Ervin currently serves as an independent director of Cingulate, Inc. (Nasdaq: CING), a biopharmaceutical company focused on the development of new product candidates for the treatment of central nervous system.

Mr. Ervin has no family relationship (within the meaning of Item 401(d) of Regulation S-K) with any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company. There has been no transaction since the beginning of the Company's last fiscal year, and there is no currently proposed transaction, in excess of $120,000 in which the Company is or was a participant and in which Mr. Ervin or any of his immediate family members (within the meaning of Item 404 of Regulation S-K) had or will have a direct or indirect material interest.

*Ervin Employment Agreement*

 ****

In connection with Mr. Ervin's appointment as Chief Financial Officer of the Company, the Company and Mr. Ervin entered into an Employment Agreement, dated as of July 1, 2025 (the "Employment Agreement"), pursuant to which Mr. Ervin will serve as the Company's Chief Financial Officer on a part-time basis. The material terms and conditions of the Employment Agreement are summarized below.

The Employment Agreement provides for a $175,000 annual base salary (the "Base Salary"). In the event that the Mr. Ervin's employment is terminated by the Company as a result of a Change-of-Control (as defined in the Employment Agreement), the Company agreed to provide Mr. Ervin with severance pay in an amount equal to six months' pay at his final Base Salary rate, payable in the form of salary continuation.

The preceding description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit Number</u> <u>Description</u> <br> 10.1 [Employment Agreement, dated as of July 1, 2025, by and between Allarity Therapeutics, Inc. and Jeffrey S. Ervin.](ea024823801ex10-1_allarity.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Allarity Therapeutics, Inc.** | **Allarity Therapeutics, Inc.** |
| Date: July 7, 2025 | By: | /s/ Thomas H. Jensen |
|  |  | Thomas H. Jensen |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**EMPLOYMENT AGREEMENT**

BETWEEN

**Allarity Therapeutics, Inc.**

AND

**Jeffrey S. Ervin**

This **Employment Agreement** (the "<u>Agreement</u>") is entered into on July 1, 2025 (the "<u>Effective Date</u>"), by and between **Allarity Therapeutics, Inc**., a corporation organized under the laws of the state of Delaware, with an office at 123 E. Tarpon Ave., Tarpon Springs, FL 34689 (the "<u>Company</u>") and **Jeffrey S. Ervin**, an individual residing at [XX] (the "<u>Executive</u>"). The Company and the Executive may collectively be referred to herein as the "<u>Parties</u>" or separately as a "<u>Party</u>".

Now, therefore, in consideration of the mutual covenants and undertakings of each Party herein, the Parties agree as follows:

1. Appointment

1.1 The Executive shall be employed as the Chief Financial Officer (CFO) of the Company and will, if required
by applicable law, be registered as such with the U.S. Securities and Exchange Commission (SEC) and/or U.S. Nasdaq stock market.

1.2 This Agreement (including Appendix 1 and 2) sets forth the entire agreement between the Parties with respect
to the employment of the Executive, and shall supersede all prior employment agreements, promises, and understandings (either oral or
written) between the Parties.

2. Duties

2.1 Without prejudice to the duties imposed by law, the Executive shall, to the best of his/her ability, promote,
develop and further the interests of the Company, comply with all applicable legal requirements and the Company's applicable policies
and procedures that have been furnished to him/her, and, subject to the terms of this Agreement, shall devote sufficient working time
to the business and the affairs of the Company. This Agreement shall not be construed as preventing the Executive from engaging in other
pre-approved business activities, charitable and community affairs, participating in industry trade association activities, or giving
attention to his/her or his/her family's passive investments, provided that such activities do not unreasonably interfere with the
Executive's duties and responsibilities to the Company. Passive investments shall mean publicly traded stocks, bonds, retirement
funds or other similar investments, including investments in privately held companies so long as any such investment does not require
any material amount of time or attention of the Executive during the work day.

2.2 The Executive shall report to the Chief Executive Officer of the Company (" <u>CEO</u> ") and
the Executive shall perform such duties and exercise his/her powers, authorities and decisions, consistent with his/her position as the
Executive as well as any such other duties and responsibilities as determined by the CEO or the Company's Board of Directors (the
" <u>Board</u> ") from time to time, within/under the conditions and restrictions, delegated to the CFO by the CEO or the Board.
The Executive shall also interface, as required or requested, with the Audit Committee of the Board.

2.3 Subject to the directives of the CEO and the terms of this Agreement, the Executive shall do all acts
and things in the ordinary course of business of the Company consistent with his/her position as Executive, which may be necessary or
conducive to the interest of the Company and in particular, but without prejudice to the generality of the foregoing, the Executive shall
be responsible for the day-to-day advancement of the Company's business goals and activities within his/her area of responsibility,
and shall participate as part of executive management of the Company.

2.4 The day-to-day responsibilities of the Executive do not include decisions/acts, which, compared to the
business of the Company or the specific situation of the Company, are considered outside of the ordinary conduct of business and reasonably
would be expected to have material impact on the business of the Company. Such decisions/acts must always be submitted to the Board for
prior approval, unless such approval cannot be awaited without the business of the Company being subject or exposed to a material adverse
impact therefrom. In the event that prior approval has not been obtained, the Board must be informed in writing of any decisions/acts
made as soon as practicable.

2.5 The Executive shall be responsible, as soon as practicable after he/she becomes aware thereof, for adequately
informing the Board or the Audit Committee of any facts that reasonably would be expected to have a material impact on the Company's
business activities and that have not previously been disclosed to the Board.

3. Location and Hours

3.1 The Executive will primarily work remotely from his/her home in Tennessee. The Executive shall engage
in travel, including international travel, as reasonably may be required by the Company's business, and it is anticipated that the
Executive will travel to the Company's U.S. headquarters and/or R&D headquarters in Denmark, or other locations as required,
as requested by the CEO and/or as necessary to advance the goals and activities of the Company.

3.2 The Executive is an exempt employee under the federal Fair Labor Standards Act ("FLSA") and
applicable state law. As such, no additional compensation beyond that described in Section 7.1 is due for any additional hours worked
beyond 40 hours in a work week.

4. Engagement in Other Business

4.1 The Executive has advised the Company of any other board roles held by Executive, as of the Effective
date of this Agreement, which other board roles are listed on Appendix 2 attached hereto. The Executive shall be permitted to serve on
the board of directors of other companies that are not in competition with the Company and only with the approval of the Board, which
shall not unreasonably be withheld, provided that it is acknowledged and agreed that the Board shall not be required to approve the Executive's
service on the board of directors of more than two (2) companies at any time.

4.2 It is a prerequisite for any involvement in other businesses, except such involvement as expressly permitted
in this Agreement, that the Executive submits a written request to the Board for approval and that the written request contains an adequate
description of the character and the volume of the task. The Board may grant the Executive's request for approval of permission
to perform such other task in his/her sole discretion, and shall communicate its approval or rejection of the request in writing.

5. Duty of Confidentiality

5.1 The Executive is under an obligation to protect the interests of the Company at all times and may not,
except in the proper performance of the Executive's services under this Agreement, disclose to any third party any Confidential
Information obtained in the performance of the Executive's services. For purposes of this Agreement, Confidential Information means
all data, information, ideas, concepts, discoveries, trade secrets, inventions (whether or not patentable or reduced to practice), innovations,
improvements, know-how, developments, techniques, methods, processes, treatments, drawings, sketches, specifications, designs, plans,
patterns, models, plans and strategies, and all other confidential or proprietary information or trade secrets in any form or medium (whether
merely remembered or embodied in a tangible or intangible form or medium) whether now or hereafter existing, relating to or arising from
the past, current or potential business, activities and/or operations of the Company or any of its affiliates (or any of their respective
predecessors, successors or permitted assigns), including, without limitation, any such information relating to or concerning finances,
sales, marketing, advertising, transition, promotions, pricing, personnel, customers, suppliers, vendors, partners and/or competitors.
Provided that, Confidential Information does not include information which (i) is already publicly available or becomes publicly available;
(ii) is already generally known in the industry or becomes generally known in the industry without the Executive's participation
in violation of his/her obligations under this Section 5; and/or (iii) is independently derived by the Executive without reference to
any Confidential information disclosed to the Executive by the Company, as established by written records. In the event of uncertainty
as to whether or not certain information may be disclosed, the Executive shall consult the CEO or the Board.

For purposes of this Agreement, "trade secrets" shall be given its broadest possible interpretation under the Defend Trade Secrets Act of 2016, and shall include (without limitation) all forms and types of financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs, or codes, whether tangible or intangible, and whether or how stored, that is compiled, or memorialized physically, electronically, graphically, photographically, or in writing by the Company.

The Executive acknowledges and understands that: (i) the Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law; (ii) the Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; (iii) if the Executive files a lawsuit for retaliation for reporting a suspected violation of law the Executive may disclose the trade secret to the Executive's attorney and use the trade secret information in the court proceeding, provided the Executive files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.

5.2 Notwithstanding the foregoing, nothing contained in this Agreement shall prohibit the Executive from disclosing
Confidential Information to the extent necessary as required by law, including in connection with reporting possible violations of federal
law or regulation to any governmental agency or entity, or making other disclosures that are protected under the whistleblower provisions
of applicable law or regulation. Provided that, the Executive shall first provide notice of such legal requirement to the Company in order
to enable the Company to take appropriate legal action to protect such Confidential Information.

5.3 The Executive is further prohibited from using or disclosing any confidential, proprietary or trade secret
information of any former employer or other person to whom he/she has an obligation of confidentiality. The Executive will be required
to use only information that is not subject to any confidentiality or non-use obligation owed to any third party (either under applicable
law or by contract), is generally known and used by persons with training and experience comparable to the Executive's, is common
knowledge in the industry or otherwise legally in the public domain or is otherwise provided or developed by or on behalf of the Company.
The Executive agrees that he/she will not bring onto Company premises or use in his work for the Company any unpublished documents or
property belonging to any former employer or third party that the Executive is not authorized to use and disclose. The Executive further
represents that he has disclosed to the Company any contract he/she may have signed that might restrict Executive's activities on
behalf of the Company. By accepting employment with the Company, the Executive is representing that he/she will be able to perform his/her
duties set out in this Agreement within these parameters.

5.4 Upon termination of this Agreement, or earlier if requested by the CEO and/or the Board, the Executive
shall immediately return to the Company all Confidential Information, including notes, memoranda, documents and records (whether tangible
or electronically stored) concerning the business of the Company, but excluding such documents that relate to Executive's own compensation
and benefits, or to any continuing ownership interest he may have in the Company. The Executive's duty of confidentiality set forth
in this Section 5 also shall continue in force after the termination of his/her employment with the Company.

6. Intellectual Property Rights

6.1 The Executive acknowledges and agrees that all ideas, methods, inventions, discoveries, improvements,
work products, developments, software, know-how, processes, techniques, works of authorship and other work product, whether patentable
or unpatentable, that are (A) conceived and reduced to practice, created, invented, designed, developed, contributed to, or improved with
the use of any Company resources and/or within the scope of the Executive's work with the Company or that relate to the business,
operations or actual or demonstrably anticipated research or development of the Company, and that are made or conceived by the Executive,
solely or jointly with others, during his/her employment, and/or (B) suggested by any work that the Executive performs in connection with
the Company during his/her employment and related to the business, operations or actual or demonstrably anticipated research and development
of the Company, either while performing his/her duties with the Company or on his/her own time, shall belong exclusively to the Company
(or its designee), whether or not patent or other applications for intellectual property protection are filed thereon (the " <u>Inventions</u> ").
The Executive hereby irrevocably conveys, transfers and assigns to the Company the Inventions and all patents or other intellectual property
rights that may issue thereon in any and all countries, whether during or subsequent to the Executive's employment, together with
the right to file, in the Executive's name or in the name of the Company (or its designee), applications for patents and equivalent
rights. The Executive agrees to reasonably assist the Company with any required inventor assignments and/or declarations necessary to
effect such patent filings, at the expense of the Company.

6.2 Such rights include inventions, creations, designs, use patterns, trademarks and other marks as well as
copyrights and associated rights including, to the extent possible, moral rights and rights in applicable rules of law and rights in know-how.

6.3 The assignment includes any right, which may be exercised at any time under the rules of law in any jurisdiction
whatsoever. The assignment is subject to no restrictions whatsoever, and the Company is entitled to reassign such rights in whole or in
part.

6.4 The Executive is not entitled to receive financial compensation for such intellectual property; as such,
payment is included in the agreed compensation described in this Agreement.

6.5 At the Company's request, the Executive shall execute and deliver to the Company any and all applications,
assignments or other instruments and perform such other acts to assist the Company in applying for obtaining patents, copyrights and other
intellectual property rights recognized by the U.S. or any foreign country or to otherwise protect the Company's interests therein.
The Executive agrees to provide the Company all information known to or ascertainable by him and all documents and other materials and
objects pertaining to the Company's rights in the Inventions that are in the possession of or accessible to the Executive, and further,
at any trial, hearing, deposition, or other legal proceeding where Executive is called as a witness by the Company, the Executive agrees
to testify to all facts pertaining to the Company's rights in the Inventions for which the Executive is competent to testify. The
obligations set forth in this Section 6 shall continue beyond the termination of the Executive's employment with the Company and
shall be binding upon his assigns, executors, administrators and other legal representatives. In the event the Company is unable to secure
the Executive's signature on any document necessary to apply for, prosecute, obtain, or enforce any patent, copyright, or other
right to protection relating to any Inventions, whether due to mental or physical incapacity or any other cause, the Executive hereby
irrevocably designates and appoints the Company and each of its duly authorized officers and agents as his or her agent and attorney-in-fact,
to act for and in his behalf and stead to execute and file any such document and to do all other lawfully permitted acts to further the
prosecution, issuance and enforcement of patents, copyrights, or other rights or protections with the same force and effect as if executed
and delivered by the Executive.

7. Compensation and Benefits

7.1 The Executive shall receive an annual base salary of one-hundred seventy-five-thousand dollars (US$175,000.00)
(the " <u>Base Salary</u> "). The Base Salary shall be subject to all customary and legally required deductions and withholdings
and shall be paid semi-monthly in accordance with the Company's regular payroll schedule for U.S. executives and employees.

7.2 The CEO and Compensation Committee of the Board shall review the Executive's base salary on a semi-annual
basis for a performance-based merit increase, which may be granted in the Company's sole discretion.

7.3 Reserved for Future Use.

7.4 The Company may or has provide(d) the Executive with a laptop computer, cell phone, and/or other electronic
devices, at no cost, and the Company may pay all costs relating to such electronic devices according to the Company Benefits policy. The
Executive's use of such provided electronic devices is subject to the Company IT policy. The Executive may be required to return
his/her laptop and all other Company property to the Company upon termination of employment with the Company (or earlier if requested
by the Company).

8. Expenses

8.1 The Company shall pay for, or refund to the Executive, all reasonable, documented business expenses related
to travel or otherwise in connection with the performance of his/her duties on behalf of the Company, upon the presentation of receipts
and in accordance with applicable Company policies for travel, meals, lodging and other relevant expenses. Upon the Executive's
request, the Company may provide Executive with a corporate credit card, which Executive may utilize to pay for all reasonable business
expenses.

8.2 The Executive shall, no later than sixty (60) days after the end of each calendar month submit all travel
and other expenses, if any, incurred within such month to the Company. The Executive shall prepare an expense report, which encompasses
documentation for the expenses reclaimed, and the expense reports with attached receipts shall be submitted to the Company's CEO
for approval, prior to the Company's reimbursement (or for accounting records if the Executive has charged such expenses on his/her
corporate credit card). The Company will reimburse the Executive within thirty (30) days of such submission of expenses for reimbursement.

9. Vacation Time

9.1 The Executive shall be entitled to unlimited paid vacation time subject to the operational needs of the
Company.

10. Term & Termination

10.1 This Agreement shall come into force as of the Effective Date and shall continue in force and effect until
otherwise terminated as provided below.

10.2 This Agreement shall terminate immediately upon the Executive's death.

10.3 This Agreement shall terminate upon written notice by the Company to the Executive that Executive's
employment is being terminated as a result of Executive's Disability (as defined in Section 10.9), which termination shall be effective
on the date of such notice or such later date as specified in writing by the Company.

10.4 This Agreement shall be terminable in writing by either the Company or the Executive with thirty (30)
days' prior written notice. At the election of the Board in its sole discretion, the termination of the Executive's employment
may be accelerated to any date selected by the Board, and the Executive shall be paid his/her compensation under this Agreement through
the date that the Executive would have been paid without such acceleration.

10.5 In the event that the Executive's employment is terminated by the Company as a result of a Change-of-Control
(as defined in Section 10.7), the Company shall provide the Executive with severance pay in an amount equal to six (6) months' pay
at the Executive's final Base Salary rate, payable in the form of salary continuation.

10.6 Any obligation of the Company to provide the Executive with the payments described in Section 10.5 is
conditioned upon the Executive signing a timely and effective general release of claims substantially in the form attached to this Agreement
as **Appendix 1** and the Executive's continued compliance with the terms of this Agreement. Such release shall be considered
timely if it is executed and delivered (and no longer subject to revocation, if applicable) within forty-five (45) days following the
date of the termination of the Executive's employment, and any payments to which the Executive is entitled pursuant to this Section
10 shall commence on the Company's first regular pay date following the effective date of the aforementioned release of claims and
the first such payment shall be retroactive to the day immediately following the date of the termination of the Executive's employment.

10.7 For the purpose of Section 10.5, "Change-of-Control" shall mean the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a change of control as defined in the Company's 2021 Equity Incentive Plan or any other change of control agreement or plan
to which the Company is a party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the occurrence of, or execution of an agreement providing for, (A) a merger, consolidation, division or
other fundamental transaction involving the Company, (B) a sale, exchange, transfer or other disposition of substantially all of the assets
of the Company, or (C) a purchase by the Company of substantially all of the assets of another entity, unless (y) such merger, consolidation,
division, sale, exchange, transfer, purchase, disposition or other transaction is approved in advance by eighty percent (80%) or more
of the members of the Board who are not interested in the transaction and (z) a majority of the members of the board of directors of the
legal entity resulting from or existing after any such transaction and a majority of the board of directors of such entity's parent
Company, if any, are former members of the Board; or

10.8 If this Agreement is terminated as a result of the Executive's death, disability or incapacity,
all payments, salary and the accrual of other benefits hereunder shall cease at the effective date of termination, other than rights to
indemnification, directors' and officers' liability insurance coverage and vested rights under the benefit plans and programs
of the Company. For the avoidance of doubt, the Executive shall be entitled to receive from the Company upon termination for any reason:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) all Base Salary earned but not yet paid through the date that the Executive's employment is terminated,
plus any earned and unpaid Annual Bonus for the calendar year prior to the year in which the termination occurs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) reimbursement for any and all reasonable business expenses incurred by the Executive through the date
that the Executive's employment is terminated in accordance with Section 8 of this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) continuation of rights to indemnification and directors' and officers' liability insurance
coverage; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) all other vested payments and/or vested benefits to which the Executive may be entitled under the terms
of any applicable compensation arrangement or benefit plan or program of the Company.

10.9 For purposes of this Agreement, "Disability" shall mean the Executive's incapacity or
inability to perform the Executive's duties and responsibilities as contemplated herein for 120 days or more within any one (1)
year period (cumulative or consecutive) because the Executive's physical or mental health has become so impaired as to make it impossible
or impractical for the Executive to perform the duties and responsibilities contemplated hereunder. Determination of the Executive's
physical or mental health shall be determined by the Company after consultation with a health care provider appointed by mutual agreement
between the Company and the Executive (or the Executive's authorized representative) who has examined the Executive. The Executive
hereby consents to such examination and consultation regarding the Executive's health and ability to perform as aforesaid. It shall
have no impact on the Company's right to terminate the employment whether the Executive is reported fit for duty following the serving
of notice.

10.10 In the event the Executive is declared incapable of managing his/her own affairs, the Company shall be
entitled to terminate the employment without prior notice.

11. Withholdings

All payments made pursuant to this Agreement shall be subject to withholding of applicable income and employment taxes. The Company may withhold from any payments made under this Agreement all authorized or legally required deductions and withholdings, including but not limited to income, employment and social insurance taxes. Except as expressly provided for in this Agreement, nothing in this Agreement shall create any obligation on the part of the Company to indemnify, reimburse, gross up, or otherwise compensate the Executive for any taxes, interest, penalties, costs, losses, damages, or expenses arising out of any violation of tax laws or any corresponding provision of law.

12. Restrictive Covenants

12.1 The Executive acknowledges that: (i) the Executive performs services of a unique nature for the Company
that are irreplaceable, and that the Executive's performance of such services for a Competing Business (as defined below) will result
in irreparable harm to the Company; (ii) the Executive will have access to Confidential Information, which, if disclosed, would unfairly
and inappropriately assist in competition against the Company or any of its affiliates; (iii) the Company and its affiliates have substantial
relationships with their clients, business partners, and investors, and the Executive will have access to these persons and entities;
(iv) the Executive will generate goodwill for the Company and its affiliates in the course of the Executive's employment. Accordingly,
for good and valuable consideration, including the compensation set forth in Section 7 of this Agreement, the receipt and sufficiency
of which is hereby acknowledged, during the Executive's employment hereunder and during the six (6) month period after the Executive's
employment terminates for any reason (the " <u>Restricted Period</u> "), the Executive agrees that he/she will not, directly
or indirectly, own, manage, operate, control, be employed by (whether as an employee, consultant, independent contractor or otherwise,
and whether or not for compensation) or render services to any person, firm, corporation or other entity, in whatever form, engaged in
a Competing Business, or with respect to which the Company has spent significant time or resources analyzing for the purposes of engaging,
on the date of termination, in any state of the United States, in Europe, or in any country in which the Company conducts business or
has made plans and taken significant steps to conduct business (a " <u>Planned Competing Business</u> ") and in which the Executive,
during the last two years of his/her employment, provided services or had a material presence or influence. Notwithstanding the foregoing,
nothing herein shall prohibit the Executive from being a passive owner of not more than 2% of the equity securities of a publicly traded
corporation engaged in a Competing Business or Planned Competing Business, so long as the Executive has no active participation in the
Competing Business or Planned Competing Business of such corporation. For purposes of this Section 12.1, the " <u>Company</u> "
shall mean the Company together with its parent companies and its and their direct and indirect subsidiaries, and " <u>Competing Business</u> " shall mean the research, development and/or sale of cancer therapeutics together with drug efficacy prediction technology
(*e.g*. companion diagnostics, predictive biomarkers) for the treatment of cancer, including, without limitation, products or services
designed to make such technology available to patients and businesses in the healthcare industry, or any other material business in which
the Company is engaged as of the date of the Executive's termination of employment. For the avoidance of doubt, the provisions of
this Section 12.1 will not prohibit the Executive, after termination of his/her employment with the Company, from providing services of
any nature to any business engaged in multiple business activities, including activities that would constitute a Competing Business or
a Planned Competing Business, as long as the Executive is not himself/herself directly involved in such Competing Business or Planned
Competing Business activities, or managing or supervising the conduct of such Competing Business or Planned Competing Business activities.
During the Restricted Period, the Executive agrees that he/she shall not, except in the furtherance of his/her duties hereunder, directly
or indirectly, individually or on behalf of any other person, firm, corporation or other entity, do business with, solicit, aid or induce
(or attempt to do business with, solicit, aid or induce) any individual or entity that is, or was during the twelve (12) month period
immediately prior to the termination of the Executive's employment for any reason, a customer, partner or investor of the Company
or any of its subsidiaries or affiliates with which the Executive had contact on behalf of the Company or about which the Executive possesses
Confidential Information to limit or cease doing business with the Company, or otherwise interfere with the relationship of such customer,
partner or investor with the Company or any of its subsidiaries or affiliates.

12.2 During the Restricted Period, the Executive agrees that the Executive shall not, except in the furtherance
of the Executive's duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or
other entity: (i) solicit, aid or induce (or attempt to solicit, aid or induce) any advisor, consultant, employee, representative or agent
of the Company or any of its subsidiaries or affiliates to leave such employment or engagement with the Company or solicit, aid or induce
(or attempt to solicit, aid or induce) any employee of the Company or any of its subsidiaries or affiliates to accept employment with
or render services to or with any other person, firm, corporation or other entity unaffiliated with the Company or hire or retain any
such employee, or take any action to materially assist or aid any other person, firm, corporation or other entity in identifying, hiring
or soliciting any such employee, representative or agent; or (ii) interfere, or aid or induce (or attempt to interfere, aid or induce)
any other person or entity in interfering, with the relationship between the Company or any of its subsidiaries or affiliates and any
of their respective vendors, joint venturers or licensors. Any person described in this Section 12.3 shall be deemed covered by this Section
while so employed or retained by the Company. For the avoidance of doubt, the general recruitment or solicitation of employees or other
third parties by any entity with which the Executive is or may be affiliated (*e.g*. internet job postings), or the hiring or engagement
of any such person or entity as a result of such general recruitment or solicitation, will not be a breach of Sections 12.2 or 12.3, unless
such recruitment or solicitation is specifically targeted at any employees or other third parties engaged by or providing services to
the Company.

12.3 The Executive agrees not to make negative comments or otherwise disparage the Company or any of its affiliates
or any of their respective partners, members, officers, directors, employees, shareholders, agents or products. The Company agrees that
it shall take reasonable efforts to cause the executive officers of the Company as of the date of the Executive's termination and
the members of the Board as of the date of the Executive's termination not to make negative comments about the Executive or otherwise
disparage the Executive in any manner that is likely to be harmful to the Executive's business reputation. The foregoing shall not
be violated by truthful statements in response to legal process, required governmental testimony or filings, or administrative or arbitral
proceedings (including, without limitation, depositions in connection with such proceedings).

12.4 If it is determined by a court of competent jurisdiction in any state that any restriction in this Section
12 is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the Parties that
such restriction shall be modified or amended by the court to render it enforceable to the maximum extent permitted by the laws of that
state.

12.5 The Parties acknowledge and agree that the remedies at law for a breach or threatened breach of any of
the provisions of Section 12.1-12.4 hereof would be inadequate and, in recognition of this fact, each Party agrees that, in the event
of such a breach or threatened breach by the other Party, in addition to any remedies at law, the Party seeking to enforce the provisions
of this Agreement shall be entitled to seek equitable relief in the form of specific performance, a temporary restraining order, a temporary
or permanent injunction or any other equitable remedy which may then be available, without the necessity of showing actual monetary damages
or the posting of a bond or other security. In the event of a violation by the Executive of any provision of Sections 5 or 6 of this Agreement,
or this Section 12, following the termination of the Executive's employment under this Agreement, any payments or other benefits
being paid or provided to the Executive pursuant to Section 10 of this Agreement shall immediately cease.

13. Code Section 409A

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Notwithstanding the foregoing, if necessary to comply with the restriction in Section 409A(a)(2)(B) of
the Internal Revenue Code of 1986, as amended (the "Code") concerning payments to "specified employees", any payment
on account of the Executive's separation from service that would otherwise be due hereunder and which is subject to the requirements
of Code Section 409A that is payable within six (6) months after such separation shall nonetheless be delayed until the first business
day of the seventh month following the Executive's date of termination and the first such payment shall include the cumulative amount
of any payments that would have been paid prior to such date if not for such restriction, plus interest on any delayed payments at the
prime rate of interest published in the Wall Street Journal effective as of the date of termination. Notwithstanding anything contained
herein to the contrary, the Executive shall not be considered to have terminated employment with the Company for purposes of his/her voluntary
termination or his/her termination by the Company without cause unless he/she would be considered to have incurred a "termination
of employment" from the Company within the meaning of Treasury Regulation §1.409A-1(h)(1)(ii).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) This Agreement is intended to be exempt from or comply with the requirements of Section 409A of the Code
and regulations promulgated thereunder ("Section 409A"). To the extent that any provision in this Agreement is ambiguous as
to its compliance with Section 409A, the provision shall be read in such a manner so that no payments due under this Agreement shall be
subject to an "additional tax" as defined in Section 409A(a)(1)(B) of the Code. For purposes of Section 409A, each payment
made under this Agreement shall be treated as a separate payment. In no event may the Executive, directly or indirectly, designate the
calendar year of payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements
of Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during the Executive's
lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during
a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible
expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the
right to reimbursement is not subject to liquidation or exchange for another benefit.

14. Limitation as to Amounts Payable

14.1 Notwithstanding anything set forth in this Agreement to the contrary, if any payment or benefit the Executive
would receive from the Company (or its successor) pursuant to a Change of Control Event or otherwise ("Payment") would (i)
constitute a "parachute payment" within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject
to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then such Payment shall be reduced to the Reduced
Amount. The "Reduced Amount" shall be the largest portion of the Payment that would result in no portion of the Payment being
subject to the Excise Tax. If a reduction in payments or benefits constituting "parachute payments" is necessary so that the
Payment equals the Reduced Amount, reduction, unless to the extent permitted by Code Section 280G the Executive designates another order,
shall occur in the following order: reduction of cash payments; cancellation of accelerated vesting of equity awards not subject to Q&A
24(c) of Treasury Reg. 1.280G 1; cancellation of accelerated vesting of Stock Options, stock options and other equity awards subject to
Q&A 24(c) of Treasury Reg. 1.280G 1; reduction of employee benefits. In the event that acceleration of vesting of warrant, stock option
or equity award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant
of the Executive's Stock Options, stock options or equity awards. The accounting firm engaged by the Company for general audit purposes
as of the day prior to the effective date of the Change of Control shall perform the foregoing calculations, or if such accounting firm
is not authorized to provide services in the United States or otherwise not qualified to advise with regard to United States taxation,
then an accounting firm shall be retained by the Company that is so authorized and qualified. Notwithstanding the foregoing, if this Section
14 would result in the reduction in any Payment, the Company will use good faith efforts to submit the excess Payments for stockholder
approval such that, if approved, the excise tax under Section 4999 of the Code (and therefore the limits imposed by this Section) does
not apply to the Executive thereby allowing such excess Payments to be paid to the Executive.

15. Waiver of Breach

A waiver by the Company or the Executive of any breach of any provision of this Agreement by the other Party shall not operate or be construed as a waiver of any other or subsequent breach by the other Party.

16. Tolling

The Executive understands and agrees that in the event that the Executive breaches any covenants contained herein during the Restricted Period, the Restricted Period shall be extended automatically. The duration of such extension shall equal the period of time between the date the Executive began such violation and the date the Executive permanently ceases such violation.

17. Disclosure to Future Employers

During the Restricted Period the Executive shall provide, and the Executive acknowledges and agrees that the Company in its sole discretion similarly may provide, a copy of this Agreement to any business or enterprise that the Executive may directly or indirectly own, manage, operate, finance, join, control or in which Executive may participate in the ownership, management, operation, financing, or control, or with which Executive may be connected as an officer, director, employee, partner, principal, agent, representative, consultant or otherwise.

18. Changes in Role or Title

18.1 The Executive acknowledges that the covenants in this Agreement are given in exchange for, among other
things, employment and the terms and conditions of such employment. The covenants are not tied to the Executive's present role,
title or responsibilities. Therefore, the Executive acknowledges and agrees that the covenants contained in this Agreement shall survive
any change in the Executive's role, title, responsibilities, compensation, benefits or other terms and conditions of employment,
provided that payments and benefits are provided to the Executive pursuant to the terms of this Agreement.

19. Amendment of the Agreement

The Agreement may not be amended or modified except by a written modification signed by the Parties, except for those changes expressly reserved to the Company's discretion in this Agreement.

20. Attorneys' Fees; Mediation

20.1 In the event that any action is brought to enforce any of the provisions of this Agreement, or to obtain
money damages for the breach thereof, and such action results in the award of a judgment for money damages or in the granting of any injunction
in favor of one of the Parties to this Agreement, all expenses, including reasonable attorneys' fees, shall be paid by the non-prevailing
Party, if so awarded by a court of competent jurisdiction.

20.2 If a dispute arises from or relates to this Agreement or the alleged breach thereof, and if the dispute
cannot be settled by the Parties through negotiation, the Parties agree to submit the matter to non-binding mediation before resorting
to litigation in any court of competent jurisdiction. Either Party may initiate mediation by providing written notice to the other Party
of a request for mediation. The Parties agree to cooperate with one another in selecting the mediator from a panel of neutrals from JAMS
(or other similar organization) and in scheduling the time and place of the mediation. Each Party covenants and agrees to participate
in the mediation in good faith. Each Party agrees to pay one-half of mediator's fees and expenses and to pay the entire amount of
its own attorneys' fees and costs related to the mediation. The mediator may issue a report in writing, stating the essential findings
of fact and conclusions of law. Except as may be permitted or required by law, a party may disclose the existence, content or results
of any mediation hereunder without the prior written consent of all parties, including without limitation within any dispute brought within
a court of competent jurisdiction.

21. Governing Law and Jurisdiction

This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard to any conflict of laws principles. The validity or unenforceability of any provision of this Agreement, or any terms hereof, shall not affect the validity or enforceability of any other provision or term of this Agreement. The Parties agree that any action, demand, claim or counterclaim relating to the terms and conditions of this Agreement or to its breach shall be heard only and exclusively in the State of Florida in a federal court of competent jurisdiction and each Party hereby irrevocably submits to the exclusive personal and subject matter jurisdiction of such courts. The Executive and the Company further agree that any such dispute shall be tried by a federal court judge alone and hereby waive and forever renounce the right to a trial before a civil jury in any such dispute.

22. Assignment

The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company's business or that aspect of the Company's business in which the Executive is principally involved. The Company is not required to provide notice to or obtain consent from Executive prior to any such assignment. The Executive may not assign the Executive's rights and obligations under this Agreement.

23. Entire Agreement

This Agreement sets forth the entire and final agreement and understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, this Agreement supersedes any and all other agreements, either oral or in writing, between the Parties hereto, with respect to the subject matter hereof. No change or modification of this Agreement shall be valid unless in writing and signed by the Company and the Executive.

24. Signatures

This Agreement shall be signed by both Parties, in duplicate, and one original shall be kept by each of the Company and the Executive.

[*signature page follows*]

**IN WITNESS WHEREOF**, the Parties have set their signatures under seal on the Effective Date first written above.

Date: July 1, 2025

---

| | |
|:---|:---|
| **Allarity Therapeutics, Inc.** | **Allarity Therapeutics, Inc.** |
| by: | /s/ Thomas H. Jensen |
|  | Thomas H. Jensen |
|  | Chief Executive Officer |

---

Date: July 1, 2025

---

| |
|:---|
| **The Executive** |
| /s/ Jeffrey S. Ervin |
| Jeffrey S. Ervin |

---

**Appendix 1**

**GENERAL RELEASE**

I, **JEFF ERVIN**, in consideration of and subject to the performance by Allarity Therapeutics, Inc. (the "<u>Company</u>")<sup>1</sup> of its obligations under the Employment Agreement, dated as of July 1, 2025 (the "<u>Agreement</u>"), do hereby release and forever discharge as of the date hereof the Company and its affiliates and all present and former directors, officers, agents, representatives, employees, successors and assigns of the Company and its affiliates and the Company's direct or indirect owners (collectively, the "<u>Released Parties</u>") to the extent provided below. Unless I rescind my assent to this General Release as set forth in paragraph 8 below, this Agreement shall be effective on the eighth (8<sup>th</sup>) day after I sign it (the "Effective Date"), at which time it will become final and binding on all Parties.

1. My employment or service with the Company and its affiliates terminated as of _________________, 20__,
and I hereby resign from any position as an officer, member of the board of managers or directors (as applicable) or fiduciary of the
Company or its affiliates (or reaffirm any such resignation that may have already occurred). I understand that any payments or benefits
paid or granted to me under Section 10.5 of the Agreement represent, in part, consideration for signing this General Release and are not
salary, wages, payments or benefits to which I was already entitled. I understand and agree that I will not receive the payments and benefits
specified in the Agreement unless I execute and do not revoke this General Release within the time period permitted hereafter or breach
this General Release. I understand and agree that such payments and benefits are subject to <u>Section 13</u> of the Agreement, which
(as noted below) expressly survives my termination of employment and the execution of this General Release. Such payments and benefits
will not be considered compensation for purposes of any employee benefit plan, program, policy or arrangement maintained or hereafter
established by the Company or its affiliates. I also acknowledge and represent that I have received all payments and benefits that I am
entitled to receive (as of the date hereof) by virtue of any employment by the Company including my regular wages earned through the termination
date, payment for all accrued unused vacation, payment for all outstanding business expenses and any other form of compensation or benefit
that may be due to me.

2. Except as provided in paragraph 4 below and except as may be expressly provided in the provisions of the
Agreement which expressly survive the termination of my employment with the Company, I knowingly and voluntarily (for myself, my spouse,
my heirs, executors, administrators and assigns (the " <u>Releasors</u> ")) release and forever discharge the Company and the
other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross-claims, counter-claims, demands,
debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and attorneys' fees,
or liabilities of any nature whatsoever in law and in equity, both past and present (through the Effective Date of this General Release)
and whether known or unknown, suspected, or claimed against the Company or any of the Released Parties which the Releasors may have, arising
at any time prior to or including the Effective Date of this General Release (collectively, "Claims"). The Claims covered
by this General Release include, but are not limited to, all Claims that arise out of or are connected with my employment with, or my
separation or termination from, the Company (including, but not limited to, any allegation, claim or violation, arising under Title VII
of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; the Age Discrimination in Employment Act of 1967 (the "ADEA");
the Older Workers Benefit Protection Act (the "OWBPA"); the Equal Pay Act of 1963, as amended; the Americans with Disabilities
Act of 1990 (the "ADA"); the Family and Medical Leave Act of 1993 ("FMLA"); the Worker Adjustment Retraining and
Notification Act ("WARN"); the Employee Retirement Income Security Act of 1974 ("ERISA"); any applicable Executive
Order Programs; the Fair Labor Standards Act ("FLSA") and its state or local counterparts; any other federal, state or local
civil or human rights law, or under any other local, state, or federal law, regulation or ordinance; or under any public policy, contract
or tort, or under common law; or arising under any policies, practices or procedures of the Company; or any claim for wrongful discharge,
breach of contract, infliction of emotional distress, defamation; or any claim for costs, fees, or other expenses, including attorneys'
fees incurred in these matters (all of the foregoing collectively referred to herein as the " <u>Claims</u> ").

<sup>1</sup> Whenever the terms "Allarity Therapeutics, Inc." or the "Company" are used in this General Release, they shall be deemed to include Allarity Therapeutics, Inc. and any and all of its divisions, affiliates and subsidiaries and all related entities, and its and their directors, officers, employees, agents, successors and assigns.

3. I represent that I have not filed or asserted any cause of action, claim, charge or other action or proceeding
against the Company and to the best of my knowledge, no other person, organization or entity has done so on my behalf. I further represent
that I have made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by paragraph 2 above.

4. I agree that this General Release does not waive or release any rights or claims that I may have under
the ADEA which arise after the Effective Date of this General Release. I acknowledge and agree that my separation from employment with
the Company in compliance with the terms of the Agreement shall not serve as the basis for any claim or action (including, without limitation,
any claim under the ADEA).

5. I agree that I hereby waive all rights to sue or obtain equitable, remedial or punitive relief from any
or all Released Parties of any kind whatsoever in respect of any Claim, including, without limitation, reinstatement, back pay, front
pay, and any form of injunctive relief. Notwithstanding the above, I further acknowledge that I am not waiving and am not being required
to waive any right that cannot be waived under law, including the right to file an administrative charge or participate in an administrative
investigation or proceeding, including with the Equal Employment Opportunity Commission; <u>provided</u>, <u>however</u>, that I disclaim
and waive any right to share or participate in any monetary award resulting from the prosecution of such charge or investigation or proceeding.
Additionally, I am not waiving any right to any severance or other surviving benefits or rights to which I am entitled under the Agreement,
including without limitation (i) those set forth in Section 10.5 of the Agreement, (ii) any claim relating to directors' and officers'
liability insurance coverage or any right of indemnification under the Company's organizational documents or otherwise, or (iii)
my rights as an equity or security holder in the Company or its affiliates.

6. In signing this General Release, I acknowledge and intend that it shall be effective as a bar to each
and every one of the Claims hereinabove mentioned or implied. I expressly consent that this General Release shall be given full force
and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding
any state statute that expressly limits the effectiveness of a general release of unknown, unsuspected and unanticipated Claims), if any,
as well as those relating to any other Claims hereinabove mentioned or implied. I acknowledge and agree that this waiver is an essential
and material term of this General Release and that without such waiver the Company would not have agreed to the terms of the Agreement.
I further agree that in the event I should bring a Claim seeking damages against the Company, or in the event I should seek to recover
against the Company in any Claim brought by a governmental agency on my behalf, this General Release shall serve as a complete defense
to such Claims.

7. I agree that neither this General Release, nor the furnishing of the consideration for this General Release,
shall be deemed or construed at any time to be an admission by the Company, any Released Party or myself of any improper or unlawful conduct.

8. I understand that because I am over forty (40) years of age, I am granted specific rights under the Older
Workers Benefit Protection Act ("OWBPA"). I further understand that this General Release contained in Appendix 1 is intended
to release any rights I may have against the Company alleging discrimination on the basis of age. I acknowledge and agree that I have
been given twenty-one (21) days to consider and accept the provisions of this General Release and that any changes to this General Release,
whether material or immaterial, will not restart the running of this period. I further acknowledge that I understand that I may rescind
my assent to this General Release if, within seven (7) days after the date I sign the General Release, I deliver a written notice of rescission
to the Company. To be effective, such notice of rescission must be postmarked, and sent by certified mail, return receipt requested, or
hand-delivered within the seven-day period, to Allarity Therapeutics, Inc., 24 School Street, 2nd Floor, Boston, MA, Attn: Chief Executive
Officer. I agree that I will forfeit all severance payments payable by the Company pursuant to the Agreement if I challenge the validity
of this General Release. I also agree that if I violate this General Release by suing the Company or the other Released Parties, and the
Company is the prevailing Party in such suit, I will pay all costs and expenses of defending against the suit incurred by the Released
Parties, including reasonable attorneys' fees, and return all payments received by me pursuant to the Agreement. Notwithstanding
the foregoing, I shall not be deemed to forfeit any amounts payable under the Agreement solely due to a challenge to the validity of this
General Release under the requirements of the ADEA, nor shall I be required to pay the costs and expenses (including attorney's
fees) of any Released Party solely in connection with a challenge to the validity of this General Release under the ADEA, <u>provided</u>, <u>however</u>, that I acknowledge and agree that this General Release is intended to apply to all claims that I have under the ADEA and
that, unless this General Release is found to be invalid, any and all claims I have or may claim to have under the ADEA are hereby released.

9. I agree that this General Release is confidential and agree not to disclose any information regarding
the terms of this General Release (other than information made public by the Company through regulatory filings or otherwise), except
to my spouse and any tax, legal or other counsel I have consulted regarding the meaning or effect hereof or as required by law, and I
will instruct each of the foregoing not to disclose the same to anyone. Any non-disclosure provision in this General Release does not
prohibit or restrict me (or my attorney) from responding to any inquiry about this General Release or its underlying facts and circumstances
by the Securities and Exchange Commission (SEC), any other self-regulatory organization or any governmental entity.

10. I agree to reasonably cooperate with the Company in any internal investigation or administrative, regulatory,
or judicial proceeding. I understand and agree that my cooperation may include, but not be limited to, making myself available to the
Company upon reasonable notice for interviews and factual investigations; appearing at the Company's request to give testimony without
requiring service of a subpoena or other legal process; volunteering to the Company pertinent information; and turning over to the Company
all relevant documents which are or may come into my possession all at times and on schedules that are reasonably consistent with my other
permitted activities and commitments. I understand that in the event the Company asks for my cooperation in accordance with this provision,
the Company will reimburse me for all reasonable expenses related to such cooperation, provided that the Company shall not be required
to reimburse me for any attorney's fees incurred in connection with such cooperation, other than attorneys' fees otherwise
reimbursable to me pursuant to any right of indemnification I may have in accordance with the provisions of the Agreement.

11. Notwithstanding anything in this General Release to the contrary, this General Release shall not relinquish,
diminish, or in any way affect any rights or claims arising out of any breach by the Company or by any Released Party of the Agreement
after the date hereof.

12. Whenever possible, each provision of this General Release shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this General. Release is held to be invalid, illegal or unenforceable
in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect
any other provision, but this General Release shall be reformed, construed and enforced as if such invalid, illegal or unenforceable provision
had never been contained herein.

BY SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT:

● I HAVE READ IT CAREFULLY;

● I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED; TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED; THE EQUAL PAY ACT OF 1963; THE AMERICANS WITH DISABILITIES ACT OF 1990; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED;

● I VOLUNTARILY CONSENT TO EVERYTHING IN IT;

● I AM HEREBY ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO OR, AFTER CAREFUL READING AND CONSIDERATION, I HAVE CHOSEN NOT TO DO SO OF MY OWN VOLITION;

● I HAVE HAD AT LEAST TWENTY-ONE DAYS TO CONSIDER THIS GENERAL RELEASE;

● I UNDERSTAND THAT I HAVE SEVEN DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT AND THAT THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS EXPIRED;

● I HAVE SIGNED THIS GENERAL RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT; AND

● I AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY ME.

Date

**Appendix 2**

**OTHER BOARD ROLES**

Independent Director of Cingulate, Inc. (Nasdaq: CING)